Degarelix

Firmagon

GnRH Agonist SubQ FDA/EMA Label

Half-life

30 days

Time to Peak

2 days

Steady State

~150 days

Bioavailability

100%

Dose Range

80–240 mg

Frequency

Monthly

Overview

GnRH antagonist administered as a subcutaneous injection. Directly blocks GnRH receptors without the initial testosterone flare seen with GnRH agonists -- suppression begins within days. FDA-approved for advanced prostate cancer. Loading dose of 240 mg (two 120 mg injections), then 80 mg monthly maintenance.

Mechanism of Action

Competitive GnRH receptor antagonist. Directly blocks pituitary GnRH receptors, causing immediate suppression of LH, FSH, and downstream sex hormones without the initial flare effect of GnRH agonists.

Dosing Information

Route	Dose Range	Half-life	Tmax	Frequency
Subcutaneous (SubQ)	80–240 mg	30 days	2 days	Monthly

Used in Regimens

Degarelix is not currently part of any catalog regimen.

Data Sources

FDA Label Firmagon (degarelix) FDA Prescribing Information

Related Tools

Medication Level Plotter

See blood level curves for this compound

Dose Calculator

Calculate reconstitution and draw volumes

Split Dose Calculator

Divide your weekly dose into multiple injections

Track Degarelix with Doseline

Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.